# At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

> **NCT04656691** · PHASE4 · TERMINATED · sponsor: **Daniel Griffin** · enrollment: 139 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** bamlanivimab

## Key facts

- **NCT ID:** NCT04656691
- **Lead sponsor:** Daniel Griffin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-04
- **Primary completion:** 2021-04-18
- **Final completion:** 2021-04-18
- **Target enrollment:** 139 (ACTUAL)
- **Why stopped:** In April 2021 FDA revoked the Emergency Use Authorization after determining that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use.
- **Last updated:** 2022-03-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656691, "At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04656691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*